Irked by a pharma CEO's broken promise? We're making a list

FiercePharma is compiling a list of the biggest broken promises by pharma executives in recent years. (Shutterstock/Deviney Designs)

Biotech and pharma CEOs are used to having their words recorded. Whether it's at an investor conference, an industry confab, a press conference or a quarterly earnings call, CEO statements end up everywhere from webcasts to reporters' notebooks.

Sometimes, those statements aren't just facts. They're pledges of one kind or another. And while executives often hold true to their public statements, sometimes they just don't.

This fall, we’re planning to highlight the biggest promises made and broken by biopharma execs in recent years—and we’re turning to readers to help compile the list. 

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

Be it a promise not to raise prices or settle a lawsuit, a promise to hit a particular long-term sales target, a promise not to sell a company, unforeseen layoffs, misleading M&A comments or more, we want to hear your ideas for the upcoming feature. Anytime a pharma CEO said one thing and did another, that’s worth noting. 

We’ll plan to highlight a group of the broken promises in a special report this October. Please share your ideas in this form. Nominations are open until Aug. 30. Questions in the meantime? Feel free to get in touch through email or Twitter.

Read more on

Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.